Lung Cancer Clinical Trial
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Full Description
This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
Eligibility Criteria
Inclusion Criteria:
Patients must have measurable disease.
Age ≥ 18 years
Adequate renal function
Adequate liver function
Adequate hematological function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of at least three months.
Exclusion Criteria:
Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
Patients must not have had major surgery within 4 weeks before first BA3011
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 28 Locations for this study
Duarte California, 91010, United States More Info
Principal Investigator
Los Angeles California, 90027, United States More Info
Principal Investigator
Los Angeles California, 90033, United States More Info
Principal Investigator
Los Angeles California, 90048, United States More Info
Principal Investigator
Whittier California, 90603, United States More Info
Principal Investigator
Aurora Colorado, 80045, United States More Info
Principal Investigator
Fleming Island Florida, 32003, United States More Info
Principal Investigator
Fort Myers Florida, 33916, United States More Info
Principal Investigator
Saint Petersburg Florida, 33705, United States More Info
Principal Investigator
West Palm Beach Florida, 33401, United States More Info
Principal Investigator
Lexington Kentucky, 40503, United States More Info
Principal Investigator
Lexington Kentucky, 40536, United States More Info
Principal Investigator
Louisville Kentucky, 40241, United States More Info
Principal Investigator
Baton Rouge Louisiana, 70809, United States More Info
Principal Investigator
Boston Massachusetts, 02215, United States More Info
Principal Investigator
Detroit Michigan, 48202, United States More Info
Principal Investigator
Henderson Nevada, 89014, United States More Info
Principal Investigator
Las Vegas Nevada, 89169, United States More Info
Principal Investigator
New York New York, 10016, United States More Info
Principal Investigator
Pinehurst North Carolina, 28374, United States More Info
Principal Investigator
Canton Ohio, 44718, United States More Info
Principal Investigator
Cincinnati Ohio, 45219, United States More Info
Principal Investigator
Pittsburgh Pennsylvania, 15232, United States More Info
Principal Investigator
Charleston South Carolina, 29407, United States More Info
Principal Investigator
Nashville Tennessee, 37203, United States More Info
Principal Investigator
Dallas Texas, 75230, United States More Info
Principal Investigator
Kowloon , , Hong Kong More Info
Principal Investigator
Kaohsiung , , Taiwan More Info
Principal Investigator
Taichung , , Taiwan More Info
Principal Investigator
Taipei , , Taiwan More Info
Principal Investigator
Taipei , , Taiwan More Info
Principal Investigator
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.